MétaCan
Menu
Retour à la cohorte
Enregistrement W4411288963 · doi:10.1158/1557-3265.sabcs24-gs1-08

Abstract GS1-08: Association between risk-reducing surgeries and survival in young BRCA carriers with breast cancer: results from an international cohort study

2025· article· en· W4411288963 sur OpenAlexaboutno aff
Matteo Lambertini, Amir Sonnenblick, Elisa Agostinetto, Raphaëlle Bas, Maria Alice Franzoi, R. Bernstein Molho, Sabine Linn, Ava Kwong, Katarzyna Pogoda, Judith Balmañà, Ann Smeets, Jyoti Bajpai, Halle C. F. Moore, Ann H. Partridge, Kelly‐Anne Phillips, Angela Toss, Christine Rousset‐Jablonski, Fedro A. Peccatori, Tiphaine Renaud, Alberta Ferrari, Shani Paluch–Shimon, Pablo Mandó, Jeong Eon Lee, Robert Fruscio, Stephanie M. Wong, Claudio Vernieri, Kathryn J. Ruddy, Maria Vittoria Dieci, Alexios Matikas, Mariya Rozenblit, Deniz Can Güven, Minna Lee, Cynthia Villarreal‐Garza, Shelley Hwang, Laura De Marchis, Fabio Puglisi, Zoe Kemp, Pedro A. Meireles, Anastasia Parokonnaya, Gustavo Werutsky, Maiko Okano, Hatem A. Azim, Kleida Mati, Shoshana Rosenberg, Richard D. Gelber, Luca Boni, Eva Blondeaux

Notice bibliographique

RevueClinical Cancer Research · 2025
Typearticle
Langueen
DomaineBiochemistry, Genetics and Molecular Biology
ThématiqueBRCA gene mutations in cancer
Établissements canadiensnon disponible
Organismes subventionnairesnon disponible
Mots-clésMedicineOncologyBreast cancerCohortCancerInternal medicineCohort study

Résumé

récupéré en direct d'OpenAlex

Abstract Background: In carriers of germline pathogenic/likely pathogenic variants (PVs) in BRCA1 and/or BRCA2 genes, cancer risk management strategies are widely recommended. While risk-reducing salpingo-oophorectomy (RRSO) has shown to improve overall survival (OS), bilateral risk-reducing mastectomy (RRM) reduces the risk of developing breast cancer (BC) but has no proven OS benefit. Very limited evidence exists on RRSO and/or RRM specifically in BRCA carriers with prior BC diagnosis at a young age. Here we investigated the association between RRM and/or RRSO with survival outcomes in the largest global cohort of young BRCA carriers with BC. Methods: The BRCA BCY Collaboration (NCT03673306) is an international, multicenter, hospital-based, retrospective cohort study including women harboring germline BRCA1 and/or BRCA2 PVs and diagnosed between January 2000 and December 2020 with stage I-III invasive BC at the age of 40 years or younger. Patients with no information on uptake or timing of RRM and/or RRSO, or their uptake before BC diagnosis and BRCA healthy carriers were excluded. Primary endpoint was OS. Disease-free survival (DFS) and BC-free interval (BCFI) were secondary endpoints. Survival endpoints were computed from BC diagnosis. To account for potential lead time bias, in the primary analysis Cox models were used to explore the association between RRM and RRSO both included as time-dependent covariates and survival outcomes. Stratification factors were year at BC diagnosis, region/country and nodal status; OS models were also adjusted by development of distant recurrences/second primary malignancies as time-dependent covariates. In addition, sensitivity analyses were performed including a 3-year landmark analysis and a subgroup analysis including only patients tested for BRCA before or within 6 months from BC diagnosis. Results: From 109 centers in 5 continents, 5290 patients were included. Median age at BC diagnosis was 35 years (IQR 31-38). A total of 3361 (63.5%) patients were BRCA1 carriers, 2708 (51.2%) had node-negative and 2421 (45.8%) hormone receptor-positive (HR+) BC. A total of 2910 (55.0%) patients underwent RRM and 2782 (52.6%) RRSO. Median time from BC diagnosis to RRM was 0.8 years (IQR 0.5-2.7) and to RRSO was 3.0 years (IQR 1.3-6.8); median follow-up was 5.1 years (IQR 2.7-8.3) after RRM and 4.9 years (IQR 2.3-8.1) after RRSO. At a median follow-up of 8.2 years (IQR, 4.7-12.8), 686 (13.0%) OS, 1923 (36.3%) DFS and 1751 (33.1%) BCFI events were observed. RRM was associated with a significantly reduced risk of OS events (adjusted HR [aHR] 0.65, 95% CI 0.53-0.78). This association was observed irrespective of specific BRCA gene, age at BC diagnosis, tumor subtype, tumor size and nodal status. RRM was also associated with a significantly reduced risk of DFS (aHR 0.58, 95% CI 0.52-0.65) and BCFI (aHR 0.55, 95% CI 0.48-0.62) events. RRSO was associated with a significantly reduced risk of OS events (aHR 0.58, 95% CI 0.48-0.71). This association was observed irrespective of age at BC diagnosis, tumor size and nodal status. A significant interaction was observed according to specific BRCA gene (BRCA1 carriers: aHR 0.44, 95% CI 0.34-0.57; BRCA2 carriers: aHR 0.85, 95% CI 0.64-1.15) and tumor subtype (triple-negative BC: aHR 0.44, 95% CI 0.33-0.58; HR+ BC: aHR 0.80, 95% CI 0.60-1.05). RRSO was also associated with a significantly reduced risk of DFS (aHR 0.68, 95% CI 0.61-0.77) and BCFI (aHR 0.65, 95% CI 0.57-0.74) events. Sensitivity analyses provided consistent results. Conclusions: In this unique international cohort of BRCA carriers with prior BC diagnosis at a young age, RRM and RRSO were both associated with a significant improvement in OS, DFS and BCFI. These findings are critical for improving the counseling of young BRCA carriers with BC on cancer risk management strategies. Citation Format: Matteo Lambertini, Amir Sonnenblick, Elisa Agostinetto, Raphaëlle Bas, Hee Jeong Kim, Maria Alice Franzoi, Rinat Bernstein Molho, Sabine Linn, Ava Kwong, Katarzyna Pogoda, Judith Balmana, Ann Smeets, Jyoti Bajpai, Halle C.F. Moore, Ann H. Partridge, Kelly-Anne Phillips, Angela Toss, Christine Rousset-Jablonski, Fedro A. Peccatori, Tiphaine Renaud, Alberta Ferrari, Shani Paluch-Shimon, Pablo Mando, Jeong Eon Lee, Robert Fruscio, Wanda Cui, Stephanie M. Wong, Claudio Vernieri, Kathryn J. Ruddy, Maria Vittoria Dieci, Alexios Matikas, Mariya Rozenblit, Deniz Can Guven, Minna Lee, Cynthia Villarreal-Garza, Shelley E. Hwang, Laura De Marchis, Fabio Puglisi, Zoe Kemp, Pedro A. Meireles, Anastasia Parokonnaya, Gustavo Werutsky, Maiko Okano, Hatem A. Azim, Kleida Mati, Shoshana Rosenberg, Richard Gelber, Luca Boni, Eva Blondeaux. Association between risk-reducing surgeries and survival in young BRCA carriers with breast cancer: results from an international cohort study [abstract]. In: Proceedings of the San Antonio Breast Cancer Symposium 2024; 2024 Dec 10-13; San Antonio, TX. Philadelphia (PA): AACR; Clin Cancer Res 2025;31(12 Suppl):Abstract nr GS1-08.

Récupéré en direct depuis OpenAlex et désinversé. Les résumés ne sont pas conservés dans cette base de données : les index inversés représentent 8,6 Go des 9,3 Go de texte de la base, et le serveur dispose de 13 Go libres.

Comment cette classification a été obtenuedéplier

Prédiction machine sur la base complète

Imitation des enseignants

Ni prévalence calibrée, ni vérité terrain. Validation humaine à venir. Le volet Gemma est une étiquette directe du modèle pour chaque travail de la base, lue sur la notice réduite au titre. Le volet Codex est un classifieur appris des 10 348 étiquettes directes de Codex et calibré sur les taux pondérés de l'échantillon; les champs sans appui suffisant ne portent aucun appel Codex. Le mode candidate est l'union des deux volets; le consensus est leur intersection. Ces sorties portent le statut machine_predicted_unvalidated et ne sont pas des étiquettes humaines.

score de la tête « metaresearch » (Codex)0,002
score de la tête « metaresearch » (Gemma)0,004
Version: metacan-v3-hybrid-931329e0061cStatut de validation: machine_predicted_unvalidated
Catégories candidatesaucune
Catégories consensuellesaucune
DomaineSignal candidat: aucune · Signal consensuel: aucune
Devis d'étudeSignal candidat: Observationnel · Signal consensuel: Observationnel
GenreSignal candidat: Empirique · Signal consensuel: Empirique
Score de désaccord entre enseignants0,012
Score d'incertitude au seuil0,024

Scores du classifieur distillé par catégorie (deux têtes)

CatégorieCodexGemma
Métarecherche0,0020,004
Méta-épidémiologie (sens strict)0,0000,000
Méta-épidémiologie (sens large)0,0000,001
Bibliométrie0,0010,002
Études des sciences et des technologies0,0000,000
Communication savante0,0010,000
Science ouverte0,0010,001
Intégrité de la recherche0,0000,001
Charge utile insuffisante (le modèle a refusé de juger)0,0030,000

Scores machine (provisoires)

Les deux têtes enseignantes du modèle étudiant, lues sur ce travail. Un score ordonne la base pour la relecture; il n'affirme jamais une catégorie, et le statut de validation accompagne chaque rangée tel quel.

Scores de référence d'un modèle non mature (critères de maturité non atteints, 7 itérations). Un score ordonne; il n'affirme jamais une catégorie.

Tête enseignante Opus0,056
Tête enseignante GPT0,460
Écart entre enseignants0,404 · la distance entre les deux têtes enseignantes sur ce seul travail
Statut de validationscore_only:v0-immature-baseline · tel quel depuis la passe de notation : score_only signifie que le nombre peut ordonner les travaux, et qu'aucune étiquette de catégorie n'en découle

Classification

machine, non validée

Prédiction automatique; un appel candidat d’une seule source (Gemma direct ou Codex distillé), pas un consensus.

Les modèles n’ont appliqué aucune catégorie : rien dans la taxonomie ne correspondait à ce travail.
Devis d'étudeObservationnel
Domainenon disponible
GenreEmpirique

Le détail, modèle par modèle et score par score, se trouve en fin de page sous « Comment cette classification a été obtenue ».

En bref

Citations1
Publié2025
Routes d'admission1
Résumé présentoui

Explorer davantage

Même revueClinical Cancer ResearchMême sujetBRCA gene mutations in cancerTravaux en français237 207